» Articles » PMID: 14993885

Graft-versus-host Disease is Associated with a Lower Relapse Incidence After Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia

Overview
Date 2004 Mar 3
PMID 14993885
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

To determine the graft-versus-leukemia effect after hematopoietic stem cell transplantation (HSCT), we studied 199 patients with acute lymphoblastic leukemia who underwent transplantation at Huddinge University Hospital between 1981 and 2001. Seventy-four patients were in first complete remission (CR1), and 125 were in later stages of the disease. Most patients had an HLA-identical sibling donor. Conditioning consisted mainly of total body irradiation and cyclophosphamide, and graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. Acute GVHD developed in 143 patients and chronic GVHD in 67. The 5-year probability of relapse and relapse-free survival (RFS) were 32% and 49%, respectively, in patients in CR1, as compared with 53% and 33% in those with more advanced disease. In the multivariate risk factor analysis of relapse, we found that the absence of chronic GVHD (P<.001), absence of herpes simplex virus infection after HSCT (P=.003), combination prophylaxis with methotrexate and cyclosporine (P=.01), and >6 weeks from the diagnosis to CR (P=.025) were independent risk factors for relapse after HSCT. Factors associated with a better relapse-free survival were chronic GVHD (P<.001), ABO blood group mismatch (P=.006), younger patient age (P=.01), and an HLA-matched donor (P=.01). The association between herpes simplex virus infection and a low frequency of relapse is a new observation and may indicate that viral antigens play a role in the induction of an antileukemic effect.

Citing Articles

How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL.

Muffly L, Liang E, Dolan J, Pulsipher M Blood. 2024; 144(3):253-261.

PMID: 38728375 PMC: 11302453. DOI: 10.1182/blood.2023023699.


The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation.

Maurer K, Soiffer R Expert Rev Hematol. 2023; 16(12):943-962.

PMID: 37906445 PMC: 11195539. DOI: 10.1080/17474086.2023.2273847.


A pilot study of implication of machine learning for relapse prediction after allogeneic stem cell transplantation in adults with Ph-positive acute lymphoblastic leukemia.

Afanaseva K, Bakin E, Smirnova A, Barkhatov I, Gindina T, Moiseev I Sci Rep. 2023; 13(1):16790.

PMID: 37798335 PMC: 10556079. DOI: 10.1038/s41598-023-43950-w.


Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia.

Wolfl M, Qayed M, Benitez Carabante M, Sykora T, Bonig H, Lawitschka A Front Pediatr. 2022; 9:784377.

PMID: 35071133 PMC: 8771910. DOI: 10.3389/fped.2021.784377.


Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis.

Duver F, Weissbrich B, Eyrich M, Wolfl M, Schlegel P, Wiegering V PLoS One. 2020; 15(2):e0228451.

PMID: 32017805 PMC: 6999888. DOI: 10.1371/journal.pone.0228451.